Clinical Takeaway
In a small study of individuals at clinical high risk for psychosis, a single dose of CBD was found to influence the relationship between hippocampal glutamate levels and prefrontal brain activation during verbal memory tasks. This suggests CBD may act on glutamate-related signaling pathways involved in memory processing, which are known to be disrupted in early psychosis. These findings support a neurobiological basis for CBD’s potential therapeutic role, though larger trials are needed to confirm clinical relevance.
#17 A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.
Citation: Shi Yiling et al.. A single dose of cannabidiol modulates the relationship between hippocampal glutamate and learning-related prefrontal activation in individuals at Clinical High Risk of Psychosis.. Psychiatry research. Neuroimaging. 2026. PMID: 41337954.
Design: 5 Journal: 0 N: 1 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study clarifies the neurobiological mechanism by which CBD may exert antipsychotic effects in CHR populations by demonstrating that a single dose modulates the pathological coupling between hippocampal glutamate dysregulation and prefrontal dysfunction. Understanding this hippocampal-prefrontal relationship is clinically significant because it identifies a specific biomarker pathway that could predict treatment response and guide stratification of CHR patients for early intervention trials. These findings provide mechanistic support for CBD as a candidate preventive therapy in early psychosis, potentially offering a non-antipsychotic option with favorable tolerability for populations at risk of conversion to full psychotic illness.
Quality Gate Alerts:
- Preclinical only
Methodological Considerations:
- Small sample — underpowered for subgroup analysis
Abstract: BACKGROUND: Cannabidiol (CBD) is being studied as a potential intervention for the people at clinical high risk for psychosis (CHR), though the mechanisms underlying its effects are not fully understood. Previous studies indicate that a single dose of CBD can normalize alterations in memory-related brain activation and modulate hippocampal glutamate levels in the early stages of psychosis. This study aimed to examine the acute effects of CBD on the relationship between hippocampal glutamate levels and brain activation during verbal memory in individuals at CHR. METHODS: A total of thirty-three participants (n = 33) at CHR were randomly assigned to receive a single 600 mg dose of CBD (CHR-CBD) or a placebo capsule (CHR-PLB). Age-matched healthy controls (HC) (n = 19) received no study drugs. Participants underwent MRI scanning while performing a verbal learning task, and proton magnetic resonance spectroscopy to measure hippocampal glutamate levels. Effect of group x hippocampal glutamate interactions on brain activation was tested. RESULTS: CHR-PLB showed positive correlation between hippocampal glutamate levels and dorsolateral prefrontal cortex (dlPFC) (Pcorr. = 0.0039) activation compared to HC during both verbal encoding and recall. Under a single dose of CBD, the glutamate-dlPFC activation relationship was negative and significantly different compared to placebo in CHR individuals (Pcorr. = 0.0001) during both verbal encoding and recall. The reversed correlation in CBD group was also observed in the parahippocampal gyrus (Pcorr. = 0.0022) and amygdala (Pcorr. = 0.0019) during verbal recall. CONCLUSIONS: These findings suggest that CBD may normalise disrupted hippocampal-prefrontal glutamatergic coupling in CHR, highlighting its potential to target the neurochemical mechanisms underlying cognitive impairment.
🧠 This mechanistic study provides intriguing neurobiological data suggesting that a single CBD dose may modulate glutamate-related hippocampal-prefrontal connectivity in individuals at clinical high risk for psychosis, which aligns with prior findings of CBD’s effects on memory circuits and glutamate homeostasis. However, several important caveats warrant caution in interpretation: the study examines only acute single-dose effects rather than chronic dosing or clinical outcomes, the sample likely consists of relatively small numbers of CHR subjects with heterogeneous symptomatology, and the relationship between in-vivo glutamate normalization and actual psychotic symptom reduction or functional improvement remains unproven. Additionally, CBD’s effects on glutamate may be dose-dependent and variable across individuals, and this work cannot yet distinguish between direct neuroprotective mechanisms versus indirect stress-reduction effects. For clinical practice, while these findings support continued investigation of CBD as a potential CHR intervention, they do not yet justify routine use outside research settings;